NCT07145268Not yet recruitingPhase 2
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Clinical Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy
Source: ClinicalTrials.gov · Last updated 28 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Tanta University
- Diseases
- Hepatitis B
- NCT number
- NCT07145268
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 44
- From 1 Sept 2025 to the primary completion date, 1 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with prior history of liver transplantation.
- Patients with prior history of hepatocellular carcinoma.
Other illness
- Patients coinfected with HIV or HCV.
- Patients with any malignancies.
Other
- Pregnant and lactating women.
Who the study is looking for
- Patients with fibrosis stage (F2\&F3) post chronic HBV infection receiving standard antiviral therapy.
- Age \> 18 and \< 65 years.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.